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1. Introduction 
oronavirus Disease 2019 (COVID-19) 
caused by Severe Acute Respiratory Syn-
drome Coronavirus 2 (SARS-CoV-2) 
emerged in Wuhan, China in Decem-
ber 2019, and then has spread globally 
(Thompson, 2020). Coronaviruses (CoVs) are positive-
sense single-stranded RNA viruses, with a genome of 
about 26-32 kb, an average diameter of 100 nm, and 
crown-like membrane glycoproteins on the surface 
(Schoeman & Fielding, 2019; Corman, Lienau, & Wit-
zenrath, 2019b). 
The neurological symptoms, including headache, dis-
turbed consciousness, cognition impairment, and par-
esthesia have been reported in 36.4% of the COVID-19 
patients. The development of these symptoms is depen-
dent on the severity of disease so that the severely dis-
tressed patients are more susceptible to promote neu-
rological symptoms (Mao et al., 2020). Moreover, brain 
tissue edema and partial neuronal degeneration have 
also reported in the expired patients’ autopsy (Xu et al., 
2020). The genome sequencing revealed the existence 
of SARS-CoV-2in the Cerebrospinal Fluid (CSF) of af-
fected people, which demonstrates that COVID-19 has 
the potential to damage the nervous system (Wu et al., 
2020b). There are six types of CoVs known as pathogen-
ic viruses that cause severe diseases in humans (human 
coronaviruses (HCoV), including SARS-CoV, Middle 
East Respiratory Syndrome (MERS)-CoV, HCoV-
HKU1, HCoV-NL63, HCoV-OC43, and HCoV-229E. 
COVID-19 pneumonia has caused by SARS-CoV-2 , as 
the seventh known CoV, that infects humans (Corman et 
al., 2019a). The most prevailing and important types of 
CoV infections with potential nervous system involve-
ment are briefly explained below.
1.1. SARS-CoV 
SARS-CoV that causes Severe Acute Respiratory Syn-
drome (SARS) was first identified in Asia in 2003, and 
then has spread throughout the world. The most common 
symptoms of SARS are fever, chills, dry cough, and diffi-
C
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● Neuronal pathway, angiotensin-converting enzyme and blood circulation pathway are the most obvious pathways 
for SARS-CoV-2 to enter the CNS.
● Hypoxia and immune injury are the most important injuries caused by COVID-19.
● Cognition impairment is one of the problems in patients infected by COVID-19.
Plain Language Summary 
Covid-19 disease, which is caused by human infection with a type of coronavirus called SARS-CoV-2, is usually 
characterized by symptoms such as fever, dry cough, and sometimes respiratory problems. Recent research has shown 
that in more than 2% of patients, in addition to the respiratory system, infection also occurs in the nervous system. 
SARS-CoV-2 can pass the protective structures and therefore travel to the nervous system through pathways that are 
not yet well known. One of the most likely ways is through the nose. In the upper part of the nose, there are mucous 
layers that contain olfactory receptor cells. These receptor cells interact directly with olfactory neurons in the brain. The 
olfactory pathway, thereby delivers olfactory messages to the brain. If a person is exposed to an infected environment 
and the coronavirus enters his or her nose after inhalation, it is possible that the virus may spread through the olfactory 
mucosa to the central nervous system and cause brain infection. As a result of the damage that viruses cause to the 
respiratory system, the efficiency of this system for exchanging the respiratory gases will reduce, and subsequently, the 
amount of oxygen in the blood will reduce. The lack of oxygen in the blood can also lead to impaired brain function. 
Symptoms of neurological damage in patients with COVID-19 include headache, loss of consciousness, decreased 
sense of taste and smell, tingling in the limbs, and cerebrovascular disorders. Impaired nervous system and brain func-
tion might have long-term effects, and these effects may be seen in the patients even after the symptoms of the disease 
have improved. It is recommended to wear a mask during the spread of the disease to prevent the virus entry to the 
central nervous system through the respiratory system. Any disorders related to brain function in these patients should 
be taken very seriously and the necessary medical advice should be provided in this regard.
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culty in breathing. Besides, respiratory failure and death 
may happen in severe cases (Lai, Tsang, Seto, & Ooi, 
2004). Polyneuropathy, encephalitis, and aortic isch-
emic stroke are prevalent reported neurological diseases 
caused by SARS-CoV (Tsai, Hsieh, & Chang, 2005).
1.2. MERS-CoV 
MERS-CoV resulted in Middle East Respiratory Syn-
drome (MERS) in 2012. MERS originated from bats, 
and then transferred to humans through the camels, as 
an intermediate host. Patients with MERS usually ex-
perience pneumonia-related symptoms, including fever, 
myalgia, cough, and dyspnea. Severe cases have been 
reported with Acute Respiratory Distress Syndrome 
(ARDS), septic shock, multiple organ failure, and 
death. The neurological symptoms, such as disturbance 
of consciousness, paralysis, ischemic stroke, and Guil-
lain-Barre syndrome also have announced in almost 1/5 
of the MERS patients. Interestingly, these neurological 
symptoms usually appear 2-3 weeks after respiratory 
symptoms (Kim et al., 2017). 
1.3. SARS-CoV-2
SARS-CoV-2 is genetically 79.5% similar to SARS-
CoV, and its similarity to MERS-CoV is as high as 
96% (Wu et al., 2020a, 2020b). The clinical data have 
revealed the presence of symptoms similar to intracra-
nial infections, such as headache, disturbed conscious-
ness, and epilepsy in COVID-19 patients. Furthermore, 
anosmia and ageusia might also occur in these patients 
because of a sudden loss of smell or taste reported in 
the number of COVID-19 patients (Giacomelli et al., 
2020; Hopkins & Kumar, 2020). Recently, a case of 
viral encephalitis caused by SARS-CoV-2 reported in 
Beijing Ditan Hospital. Subsequent genome sequenc-
ing confirmed the presence of SARS-CoV-2 in the 
CSF of this patient, which further supports the nervous 
system damage theory by this new CoV (Xiang, Xu, 
Gao,Wang, Xiong, & Li, 2020). 
2. Probable Pathways to Enter the CNS 
2.1. Neuronal pathway 
One of the key pathways for neurotropic viruses to en-
ter the CNS and damage the nervous system is infecting 
sensory or motor nerve endings and achieving retrograde 
or anterograde neuronal transport through the motor 
proteins, dynein, and kinesins (Swanson & McGavern, 
2015). The olfactory neuron transport is one of the neu-
ronal pathways for virus entry to the CNS. The unique 
anatomical organization of olfactory nerves and the ol-
factory bulb in the nasal cavity and forebrain effectively 
represent it as a channel between the nasal epithelium 
and the brain compartments, especially the brainstem 
(Koyuncu, Hogue, & Enquist, 2013). As a consequence, 
the presence of the virus in the brainstem can damage 
the neurons involved in the regulation of respiration and 
cardiovascular activity, resulting in lung function failure 
(Steardo, Steardo, Zorec, & Verkhratsky, 2020; Net-
land, Meyerholz, Moore, Cassell, & Perlman, 2008b). 
Therefore, CoV can reach the brain structures using the 
olfactory tract in the early stages of infection or nasal 
vaccination and make inflammation and demyelinating 
reaction (Desforges, Le Coupanec, Dubeau, Bourgouin, 
Lajoie, Dubé, & Talbot, 2020; Mori, 2015). In this re-
gard, Bohmwald et al. showed that olfactory bulb re-
moval limited the invasion of CoV into the CNS in mice 
(Bohmwald, Galvez, Ríos, & Kalergis, 2018).
It has been hypothesized that the virus could spread into 
the olfactory bulb and other brain structures, especially 
the medulla oblongata in the brainstem through infecting 
the olfactory receptors in the neuroepithelium leading to 
acute respiratory failure. In this regard, Ceccarelli et al. 
using transgenic mice showed that the intranasal admin-
istration of SARS-CoV, which shares similarities with 
SARS-CoV-2, could enter the brain via the olfactory 
nerves and spread into the thalamus and brainstem (Cec-
carelli, Berretta, Venanzi Rullo, Nunnari & Cacopardo, 
2020). On the other hand, infection of the brainstem with 
the virus may impair the chemosensing neural cells asso-
ciated with respiratory and cardiovascular centers, which 
disturbs the lung ventilator action. Clinical observation 
revealed the occurrence of anosmia in SARS-CoV-2-in-
fected patients, which can confirm that the nasal route 
may contribute to the entry of the virus into the brain 
(Gandhi, Srivastava, Ray, & Tripathi, 2020).
2.2. Angiotensin-converting enzyme 2
Angiotensin-converting Enzyme 2 (ACE2), a cardio-
cerebral vascular protection factor, is reported as an 
important target for CoV and influenza virus (Turner, 
Hiscox, & Hooper, 2004). This enzyme presents in the 
nervous system and skeletal muscles and has an impor-
tant role in blood pressure regulation and anti-atheroscle-
rosis mechanisms (Miller & Arnold, 2019). In the brain, 
the ACE2 receptors have been detected in the glial cells 
and neurons, particularly in the brainstem and the regions 
responsible for the regulation of cardiovascular function, 
including subfornical organ, paraventricular nucleus, nu-
cleus tractus solitarius, and rostral ventrolateral medulla, 
making them a potential target for COVID-19 (Gowri-
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sankar & Clark, 2016; Xia & Lazartigues, 2010). It has 
been reported that SARS-CoV-2, like SARS-CoV, at-
taches to the cell membrane by interacting with the host 
ACE2 receptor using a spike protein S1 (Netland et al., 
2008a). Moreover, the binding affinity of ACE2 for the 
SARS-CoV-2 spike protein is reported 10−20-fold higher 
than the affinity for the SARS-CoV spike protein (Wang 
et al., 2020). Therefore, the virus binding to the ACE2 
receptors can lead to high blood pressure and cerebral 
hemorrhage. Moreover, because SARS-CoV-2 spike 
protein can interact with ACE2 expressed in the capillary 
endothelium, the virus may also enter the CNS through 
attacking the vascular system and damaging the Blood-
Brain Barrier (BBB) (Baig et al., 2020). 
2.3. Blood circulation pathway 
One of the known viruses affecting CNS through the 
blood circulation pathway is the Japanese encephali-
tis virus that transmits to the blood after being bitten 
by a mosquito. After reproducing in the skin vascular 
cells, the virus multiplies in the macrophages through 
the body. Thereafter, the secondary release of the vi-
rus into the blood may enhance the permeability of the 
BBB via the produced cytokines, stimulating the virus 
to enter the brain, and causing viral encephalitis (Unni, 
Růžek, Chhatbar, Mishra, Johri, & Singh, 2011). There 
are a few pieces of evidence regarding CoVs, especial-
ly SARS-CoV-2 to be entered the nervous system via 
the blood circulation pathway (Desforges et al., 2020); 
hence, further studies are required. 
3. The Most Important Injuries Caused by Cov
3.1. Hypoxia injury 
The proliferation of a virus in lung tissue cells is accom-
panied by alveolar gas exchange disorders causing hypox-
ia in the CNS and enhancing anaerobic metabolism in the 
brain cells’ mitochondria (Abdennour, Zeghal, Dème, & 
Puybasset, 2012). Brain hypoxia subsequently may cause 
cerebral vasodilation, brain cells swelling, interstitial 
edema, cerebral blood flow obstacle, and even headache 
due to ischemia and congestion (Abdennour et al., 2012). 
In the persistent hypoxia, reduced brain function can be 
followed by drowsiness, bulbar conjunctival edema, and 
even coma (Abdennour et al., 2012). In addition, hypoxia 
may also induce acute ischemic stroke in patients with a 
particular risk of developing the cerebrovascular disease. 
Because the patients with COVID-19 often suffer from 
severe hypoxia (Guo et al., 2020); therefore, hypoxia in-
jury may result in subsequent nervous system damage.
3.2. Immune injury 
A large number of SARS and COVID-19 reported deaths 
have happened due to multiple organ failure caused by vi-
rus-induced Systemic Inflammatory Response Syndrome 
(SIRS) or SIRS-like immune disorders (Chen, Zhang, 
Ju, & He, 2020). A neurotropic virus can cause chronic 
inflammation and brain damage through the activation 
of glial cells, and subsequently a massive production of 
inflammatory factors, such as cytokines, chemokines, and 
other inflammation signals. The produced inflammatory 
signals, then lead to a significant break of BBB, which 
provokes and magnifies the neuroinflammatory process 
(Wang et al., 2020b). Bohmwald et al. showed that pri-
mary glial cells cultured in vitro secrete Interleukins 
(ILs), including IL-6, IL-12, IL-15, and Tumor Necro-
sis Factor-alpha (TNF)-α after being infected with CoV 
(Bohmwald et al. 2018). Additionally, the positive cor-
relation between IL-6 and the severity of COVID-2019 
symptoms has been reported (Wan et al., 2020).
3.3. Cognition impairment
Numerous preclinical and clinical studies have provided 
evidence that systemic inflammation can perturb brain ho-
meostasis and cause neuronal death. The bacterial, viral, 
and toxic inflammation can damage glia limitans, activate 
Toll-like receptors in microglia and astrocytes, and eventu-
ally promote neuroinflammation that may result in cogni-
tive impairments (Sankowski, Mader, & Valdés-Ferrer, 
2015). Neuroinflammation induced by systemic inflam-
mation associated with prolonged hypoxia damages brain 
regions responsible for cognitive functions and behavioral 
alterations, such as the hippocampus and cortex (Sasan-
nejad, Ely, & Lahiri, 2019). Hence, the functional brain 
damage can describe the deficits in delirium, attention, and 
memory in aged patients overcoming pneumonia. Delirium 
is commonly triggered by peripheral infection associated 
with systemic inflammation and is accompanied by an el-
evated level of serum pro-interleukins and S100B (as an 
index for BBB disruption) in elderly patients (McNeil et 
al., 2019). Neuroinflammation has been implicated as an 
almost obligatory factor in neurodegenerative disorders 
(Heneka et al., 2015) and psychiatric pathologies, includ-
ing acute psychosis, schizophrenia, and autism spectrum 
disorder (Pape, Tamouza, Leboyer, & Zipp, 2019). 
There is a strong association between systemic inflamma-
tion and depressive syndromes so that infections enhance 
the risk of depressive episodes by ~60%. In animal models, 
injections of cytokines stimulated sickness behavior similar 
to a human “flu-like syndrome” characterized by anhedo-
nia, anorexia, fever, fatigue, increased pain, sleep distur-
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bances, and confusion (De La Garza, 2005). Besides, se-
vere respiratory failure accompanying COVID-19 prompts 
long-lasting hypoxia, which arguably affects the brain and 
leads to neurocognitive impairments. 
4. Conclusion
The brainstem, as one of the most important areas of 
the brain involved in infection with CoVs, has a pivotal 
controlling action on the respiratory, cardiac, and vascu-
lar systems. Therefore, the spread of respiratory failure 
and death of patients with the COVID-19 may be due to 
the weakened performance of cardiovascular and respi-
ratory centers in the brainstem. Because the most prob-
able route for viruses to enter the nervous system is the 
nasal epithelium, wearing a face mask can be effective 
to protect against virus entry into the CNS. On the other 
hand, regarding the COVID-19 neuroinvasive poten-
tial, further studies are needed to find effective antiviral 
drugs being able to cross the BBB.
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